Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06655129

Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder

The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders:

* Excessive Hairiness (Hirsutism, Hypertrichosis...) * Vascular lesions (Rosacea….) * Pigmented lesions (Lentigo et melasma) * Acne vulgaris

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CH Auxerre, Auxerre, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult men or women
  • Excessive Hairiness:
  • Patient with unwanted hair on the body (legs, arms, bikini line, or axilla)
  • Patient over 18 years.
  • Patients with Fitzpatrick skin types from I to V.
  • Women were required to be post-menopausal, surgically sterilized, or under a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, or barrier methods with spermicide or abstinence) during the study time period.

Vascular lesions:

  • Patients over 18 years.
  • Patients with Fitzpatrick skin types from I to IV.
  • Patients with varicosities and Rosacea on the face or upper and lower limbs.

Pigmented lesions:

  • Patients over 18 years.
  • Patients with solar lentigines on their cheeks, back, hands, arm and leg (> 3 mm).
  • Patient with Fitzpatrick skin type from I to IV.

Acne:

  • Patients over 18 years
  • Patients with Fitzpatrick skin types from I to IV.
  • Patients with facial acne vulgaris on face.
  • Willing to sun protect treated area for the duration of enrollment in the study and 4 weeks after treatment.

Exclusion criteria

  • Patients with history of malignant lesions or pre-malignant lesions, scarring, or infection in the area to be treated History of keloidal or hypertrophic scarring
  • Patients with a known photosensitivity
  • Pregnancy women
  • Patient with diabetes mellitus suntan in the area to be treated
  • Use of photo-sensitizing products for 7 days before treatment (selftanning lotions, activators, self-tanning shower gel, etc.)
  • Exposure to the sun or UV rays at least 4 weeks before the treatment and 1 week afterwards
  • Zones with uncovered tattoos, suspect spots or skin diseases (including spots, inflammation, beauty spots, tumors or melanomas, psoriasis, herpes...)
  • Use of medication that induces anticoagulative medication or thromboembolic condition
  • Patients with pacemaker or internal defibrillator
  • Patients that used of NSAIDS two weeks prior to or 2 weeks following the treatment
  • Epileptic patients
  • Additional criteria for excessive hair: Patients that use waxing or other methods of photo epilation within 1 month prior to treatment.
  • Additional criteria for acne: Patients currently under oral antibiotic or oral therapy for acne.

Treatment and study plan

Intense Pulsed Light

Device

intense pulsed light (IPL) using the Medical Device Anthelia

Primary outcomes

  1. Efficacity for Excessive Hairiness:

    Time frame: up to 18 months

    Excessive Hairiness by hair counting a 4cm2 surface (To demonstrate a hair reduction of 50% between the average score of the treated aera before and after a cycle of treatment defined as six sessions spaced by 12 weeks)

  2. Efficacity for Vascular lesions and Pigmented lesions

    Time frame: up to 4 months

    Vascular lesions: To demonstrate a reduction of 70% between the average score of the treated aera before and after a cycle of treatment defined as five sessions spaced by 4 weeks.

    To demonstrate a clinical improvement of 50% between the average score of the treated aera before and after a cycle of treatment defined as five sessions spaced by 4 weeks.

    Pigmented Lesions: To demonstrate a reduction of 60% between the average score of the treated aera before and after a cycle of treatment defined as three sessions spaced by 10 weeks.

  3. Efficacity for Acne vulgaris

    Time frame: up to 4 months

    measuring the diameter of each pimple in a treated area (before and after), To demonstrate a lesion reduction of 50% between the average score of the treated aera before and after a cycle of treatment defined as five sessions spaced by 2 weeks.

Secondary outcomes

  1. For all patients decrease of the IRBMS score

    Time frame: 4 to 18 months

    IRBMS (Rosenberg Self-Esteem Scale), minimum score is 10, maximum score is 40

  2. - For all patients decrease of the DLQI score

    Time frame: 4 to 18 months

    DLQI (Dermatology Life Quality Index), minimum score is 0, maximum score is 30

  3. For only Acne patients, at least 20% reduction in the ECLA score

    Time frame: 4 to 18 months

    ECLA ("Echelle de Cotation des Lésions d'Acné" or Acne Lesion Score Scale), minimum score is 0, maximum score is 36

Study contacts

Contact information is provided by the study sponsor or research team.

Laurent Zawadil

CONTACT

[email protected]

01 60 86 31 10

Sponsors and collaborators

Lead sponsor

Eurofeedback

Industry

Registry information

Official study title

Post Market Clinical Study of an Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder

Acronym: Anthelia

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Oct 23, 2024
Registry last updated
Oct 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.